linjc16/ctgov huggingface dataset:
Polymorphism of Estrogen Genes in Stroke

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the association between the genetic polymorphisms of estrogen-related genes, including estrogen synthesis, metabolizing, and receptor genes, and ischemic stroke. Furthermore, independent and joint effects of traditional risk factors and estrogen related genes on risk of stroke in young adults will also be examined in this study.

Detailed Description
-----------------
Cerebrovascular diseases are the third leading cause of death in Taiwan in 2007. It is also the most important reason for disability among elderly adults. Sex hormones are well reported to be associated with cardiovascular disease risk. Several studies showed that estrogens have been shown to have beneficial effects on the cardiovascular system via favorable effects on anti-inflammatory effects. Genetic polymorphisms of estrogen related genes are speculated to influence estrogen level and will count for human susceptible to risk of stroke in young adults. In addition, several studies showed that the decrease in estrogen-induced vascular inflammatory markers including adhesion molecules and chemokines might be the mechanism for vascular protection. Recently, a novel and unique mechanisms for 17β-Estradiol (E2) anti-inflammatory activity which is E2 prevents inflammatory gene transcription induced by inflammatory agents by inhibiting NF-κB intracellular transport was found. Therefore, we proposed a study to explore the association between the genetic polymorphisms of estrogen-related genes, including estrogen synthesis, metabolizing, receptor genes, and NF-κB and ischemic stroke in young adults.

Official Title
-----------------
Polymorphism of Estrogen Genes in Stroke

Conditions
-----------------
Ischemic Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: incident ischemic stroke patients diagnosed by CT or MRI. Exclusion Criteria: non ischemic stroke patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ischemic stroke patients<br> | |
| healthy subjects without cerebrovascular disease<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ischemic stroke patients
Ocular Surface Dry Eye Microbiome

Study Overview
=================
Brief Summary
-----------------
The investigators seek to characterize the identity of all microorganisms residing on the eye's surface (conjunctiva) in healthy eyes and those with dry eye syndrome, using a combination of analyses. Dry eye disease is thought to have an inflammatory basis and in the vast majority of cases the cause of the chronic inflammatory condition is unknown.

Official Title
-----------------
Microbiome Analysis of the Ocular Surface in Dry Eye Disease

Conditions
-----------------
Dry Eyes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: dry eye syndrome with OSDI score greater than 60 control group with OSDI score less than 30 Exclusion Criteria: recent history of contact lens wear use of topical antibiotics or prescription eye medication in past 6 months penetrating ocular surgery in the last 12 months age less than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ocular surface discomfort<br>There are no interventions with this observational study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of bacteria or fungus from conjunctival swab |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dry eye
Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
This study is a prospective, non-interventional, non-controlled, multi-center, observational cohort study. The medication is prescribed within the regular practice of the physician. Duration and dosage of treatment is solely at the discretion of the attending physician. The primary objective of this study is to assess duration of treatment in Turkish renal cell carcinoma patients treated with TKIs (Tyrosine Kinase Inhibitors) who could not tolerate prior cytokine treatment within the first month of treatment.

Official Title
-----------------
Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma

Conditions
-----------------
Renal Cell Carcinoma

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be diagnosed as metastatic renal cell carcinoma Previous cytokine therapy To sign informed consent form (ICF) Exclusion Criteria: Patients not willing to sign informed consent form or who withdraw their consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Other: No intervention<br>* All dosage, frequency and duration for drugs will be under the decision of the treating physician<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of treatment: from start of tyrosine kinase inhibitor treatment to permanent discontinuation of the product |  | After 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of treatment-emergent adverse events (TEAE) |  | After 2 years | 
| Change of Tumor status |  | Baseline and 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Renal Cell Carcinoma, TKI, Turkey, Observational
Carbohydrate and Metabolism: a Pilot Study

Study Overview
=================
Brief Summary
-----------------
The optimal choice of carbohydrate in infant formula needs to be assessed in more detail. Lactose has conventionally been used in most milk-based infant formulas, but more recently lactose-free formulas based on corn syrup solids/maltodextrins have gained in popularity. However, the metabolic consequences have not been examined. In a pilot study, the investigators will assess the postprandial metabolic response to a meal of formula with either lactose or maltodextrins. A breastfed reference group is also included.

Official Title
-----------------
Postprandial Serum Responses to Various Infant Formulas and Breast Milk in Infants- a Pilot Study

Conditions
-----------------
Infant, Metabolism

Intervention / Treatment
-----------------
* Other: Formula with lactose
* Other: Formula with maltodextrins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Term infants (gestational age 37-42 weeks) Birth weight 2500-4500g Exclusion Criteria: Infant illness Maternal diabetes Maternal pregnancy complications

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Formula with lactose<br>Carbohydrate-free formula with added lactose | Other: Formula with lactose<br> <br> |
| Experimental: Formula with maltodextrins<br>Carbohydrate-free formula with added maltodextrins | Other: Formula with maltodextrins<br> <br> |
| No Intervention: Breastfeeding<br>Breastfed reference group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose levels | The change in serum glucose levels are monitored following a test meal from baseline to 15 min, 30 min, 60 min, 90 min and 120 minutes | 2 hours (Change from baseline to 15 min, 30 min, 60 min, 90 min and 120 min) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin levels | The change in plasma insulin levels are monitored following a test meal at baseline, 15 min, 30 min, 60 min, 90 min and 120 minutes | 2 hours (Change from baseline to 15 min, 30 min, 60 min, 90 min and 120 min) | 
| Metabolite levels | The change in plasma metabolite levels are monitored (using metabolomics) following a test meal at baseline, 15 min, 30 min, 60 min, 90 min and 120 minutes | 2 hours (Change from baseline to 15 min, 30 min, 60 min, 90 min and 120 min) |
Vitamin D Supplementation in PCOS Patients

Study Overview
=================
Brief Summary
-----------------
To assess whether Vitamin D supplementations for patients with polycystic ovary syndrome in conjunction with clomiphene citrate are beneficial or not

Detailed Description
-----------------
This study is double blinded randomized controlled study conducted at Tanta University hospitals in the period from April 2019 to March 2022. Patients and methods: One hundred twelve patients were recruited and randomly allocated into 2 groups; study group with Vitamin D supplementation and control group without Vitamin D supplementation.

Official Title
-----------------
Dose Vitamin-D Supplementation Affect Reproductive Outcomes in Patients With Polycystic Ovary Syndrome?

Conditions
-----------------
PCOS

Intervention / Treatment
-----------------
* Drug: Vitamin D
* Drug: Placebo Oral Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PCOS Infertile Vitamin D deficient Exclusion Criteria: Age less than 20 and more than 35 Non PCOS patients Obese patients Previous ovarian surgery Previous oophrectomy of one ovary

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: The 2 groups will be treated at the same time
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin D group<br>These patients will receive 6000IU daily for 8 weeks then 2000IU maintenance till pregnancy or end of study | Drug: Vitamin D<br>* receive 6000iu daily for 8 weeks<br>|
| Placebo Comparator: Placebo group<br>These group will receive placebo for the same periods of study group | Drug: Placebo Oral Tablet<br>* placebo for the same period<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ovulation rate | Number of mature follicles obtained | 3 months | 
| Pregnancy rate | Number of patients who get pregnant | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pregnancy, PCOS, Vitamin D, Supplementation, Ovulation
Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes

Study Overview
=================
Brief Summary
-----------------
A Multicentre study comparing 5 different Self-Monitoring Of Blood Glucose (SMBG) system commercially available in Germany & Holland.

Official Title
-----------------
Multicentre Performance Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes Randomised to Multiple Devices

Conditions
-----------------
Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects diagnosed with type 1 or type 2 diabetes mellitus Age between 18 and 75 years. Patients with stable blood glucose in judgment of the investigator. Subjects receive intensive insulin therapy (Multiple Daily Injection defined as at least two insulin injections per day) Patients perform blood glucose self measurements on a routine basis Patients must have experience in self measurement blood glucose for at least 6 months. Exclusion Criteria: Patients with unstable blood glucose in judgment of the investigator. Patient has been diagnosed with progressive / serious diseases that in judgment of the investigator preclude successful completion of the observational period. Lack of compliance or other justifications that, in the discretion of the investigator, precludes satisfactory participation in the study. Subject without legal capacity. Blood donation within the last 30 days. Known pregnancy. Subject has already participated in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetes<br>Patients with Type 1 or Type 2 diabetes requiring insulin. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, SMBG, glucose testing systems, accuracy
Climat Impact on Urinary Iodine Concentration

Study Overview
=================
Brief Summary
-----------------
Urinary iodine concentration (UIC) is the recommended biomarker of iodine status in populations. Yet, the influence of climate on UIC remains unclear. Hot climate may reduce urine volume and consequently increase UIC independent of iodine status. This could lead to an overestimation of population iodine intake, thus masking iodine deficiency in vulnerable groups. In this longitudinal observational cohort study in women of reproductive age we will collect 24h and spot urine samples in the summer and winter season. The influence of high temperature climates on UIC, measured and estimated urinary iodine excretion will be estimated.

Official Title
-----------------
Assessment of Impact of High Temperature Climate on Urinary Iodine Concentration in Women of Reproductive Age

Conditions
-----------------
Iodine Deficiency

Intervention / Treatment
-----------------
* Other: Climate


Participation Criteria
=================
Eligibility Criteria
-----------------
Female Non-pregnant and non-lactating General good health, assessed by no reported treatment for chronic disease Non-smoking No known history of major medical illnesses or thyroid dysfunction as well as gastrointestinal or metabolic disorders and taking no chronic medication Residence at the respective study site for 12 months or longer and no plans of moving away during the study year. No use of iodine containing dietary supplements during the last 6 months No use of X-ray / CT contrast agent or iodine containing medication within the last year No use of iodine containing disinfectants during the last 6 months Participants should be between 18 and 49 years at date of enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tanzanian Women of Reproductive Age<br>Healthy women of reproductive age living in Tanzania in an area with hot and temperate climate | Other: Climate<br>* Hot and temperate climate<br>|
| South African Women of Reproductive Age<br>Healthy women of reproductive age living in South Africa in an area with hot and temperate climate | Other: Climate<br>* Hot and temperate climate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary iodine concentration | Measured in 24h urine collections | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary iodine excretion | Measured in 24 h urine collections | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Urinary iodine concentration
Micro-RNA Expression Profiles in Localised Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Recurrence free survival The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly for until death.

Official Title
-----------------
Micro-RNA Expression Profiles in Localised Prostate Cancer

Conditions
-----------------
Prostate Cancer, Radical Prostatectomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 35 Years to 80 Years Male Patients with clinically localised high risk prostate cancer Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence free survival | The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. | Up to 120 months. From date of inclusion until date of death from any cause | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cancer specific survival | Cancer specific survival | Up to 120 months. From date of inclusion until date of death from any cause |
Side Specific Withdrawal Times for Colonoscopy: Impact on Adenoma Detection in the Proximal and Distal Colon

Study Overview
=================
Brief Summary
-----------------
Adenoma detection in the main goal of screening colonoscopy. In order to detect adenomas it is mandatory to spend a long enough time investigating the colonic mucosa. A minimum observation time of 6 minutes has been proposed as a quality criterion for screening colonoscopy. However, different locations of the colon (proximal, distal) may require specific observation time periods. The colon can be divided into a proximal (right) and distal (left) part. Until now, it is unclear whether observation time has a significant impact on adenoma detection in both parts of the colon. The aim of this study therefore is to conduct a trial in which side-specific observation times and adenoma detection rates are measured in order to investigate this correlation in particular for the right colon.

Conditions
-----------------
Colon Adenoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: indication for colonoscopy age ≥ 40 years Exclusion Criteria: American Society of Anesthesiologists class IV or higher pregnant women indication for colonoscopy: inflammatory bowel disease indication for colonoscopy: polyposis syndrome indication for colonoscopy: emergency colonoscopy e.g. acute bleeding contraindication for polyp resection e.g. patients on warfarin

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Routine colonoscopy Cohort<br>Patients receiving routine colonoscopy at the study site | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenoma detection rate in the proximal colon | After obtaining the histopathological diagnosis of resected polyps (approximately 3 -6 days) it can be determined whether the resected polyp contained adenomatous histology or not. | up to 2 weeks (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 2 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Polyp detection rate | a maximum of one day is expected for colonoscopy procedures | up to one day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adenoma, Colonoscopy, Withdrawal, Proximal, Observation Time
Cognition, Steroids, and Imaging in Cushings Disease

Study Overview
=================
Brief Summary
-----------------
This study investigates the effects of the glucocorticoid hormone cortisol on brain structure and function. Patients with Cushing's disease are studied before and after treatment. Brain imaging and neuropsychologic tests are used to study changes in the hippocampus and thinking and learning functions as well as mood during the period of elevated cortisol. At several intervals after treatment, these are reexamined to study the degree of reversibility of the abnormalities. The contribution of cortisol as well as testosterone and estrogen to dysfunction and recovery is studied. Since elevated cortisol and dysregulation of its secretory system occurs in a significant proportion of the aged and in Alzheimers Disease and Major Depressive Disorder, these studies will help advance knowledge of the role of cortisol in these conditions.

Official Title
-----------------
Cognition, Steroids, and Imaging in Cushings Disease

Conditions
-----------------
Cushing Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: patients with suspected Cushing's syndrome with clinical findings suggestive of Cushing's syndrome and positive screening tests (urinary free cortisol and low dose overnight dexamethasone suppression test). Exclusion criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |